MiRNA inhibition in tissue engineering and regenerative medicine

Advanced Drug Delivery Reviews

Volumn 88, Issue , 2015, Pages 123-137

  Beavers, Kelsey R ^a   Nelson, Christopher E ^b   Duvall, Craig L ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b USA   (United States)

Author keywords

Anti miR; MiRNA; MiRNA inhibition; Regenerative medicine; Tissue engineering

Indexed keywords

REGENERATIVE MEDICINE; TISSUE; TISSUE ENGINEERING; TISSUE HOMEOSTASIS; TISSUE REGENERATION;

ANTI-MIR; BIOLOGICAL RESPONSE; MESSENGER RNAS (MRNA); MIRNA; NEGATIVE FEEDBACK MECHANISM; PATHOLOGICAL TISSUE; THERAPEUTIC APPLICATION; TISSUE ENGINEERING APPLICATIONS;

RNA;

ADENOVIRUS VECTOR; DIAZOBENZENE; DIHYDROPTERIDINONE ATP DERIVATIVE; LENTIVIRUS VECTOR; LIPOSOME; MICRORNA; MICRORNA SPONGE; NANOPARTICLE; NUCLEIC ACIDS, NUCLEIC ACID COMPONENTS AND THEIR DERIVATIVES; OLIGONUCLEOTIDE; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; MESSENGER RNA;

ANGIOGENESIS; BIOGENESIS; BONE REGENERATION; CARDIAC MUSCLE REGENERATION; CELL PROLIFERATION; COMPETITIVE INHIBITION; DRUG DELIVERY SYSTEM; HUMAN; INFLAMMATION; KIDNEY REGENERATION; LIVER REGENERATION; NONHUMAN; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; RNA SYNTHESIS; SCAR FORMATION; SKELETAL MUSCLE REGENERATION; TISSUE ENGINEERING; TISSUE REGENERATION; WOUND HEALING; ANTAGONISTS AND INHIBITORS; BONE; CARDIAC MUSCLE; GENE VECTOR; KIDNEY; LIVER; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; PROCEDURES; REGENERATION; SCAR; SKELETAL MUSCLE; TISSUE SCAFFOLD;

BONE AND BONES; CICATRIX; GENETIC VECTORS; HUMANS; INFLAMMATION; KIDNEY; LIVER; MICRORNAS; MUSCLE, SKELETAL; MYOCARDIUM; NEOVASCULARIZATION, PATHOLOGIC; REGENERATION; REGENERATIVE MEDICINE; RNA, MESSENGER; TISSUE ENGINEERING; TISSUE SCAFFOLDS; WOUND HEALING;

EID: 84937515138     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2014.12.006     Document Type: Review

References (209)

1. Weiler J., Hunziker J., Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?. Gene Ther. 2005, 13(6):496-502.
2. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., Yen Y., Heidel J.D., Ribas A. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464(7291):1067-1070.
3. Coelho T., Adams D., Silva A., Lozeron P., Hawkins P.N., Mant T., Perez J., Chiesa J., Warrington S., Tranter E., Munisamy M., Falzone R., Harrop J., Cehelsky J., Bettencourt B.R., Geissler M., Butler J.S., Sehgal A., Meyers R.E., Chen Q., Borland T., Hutabarat R.M., Clausen V.A., Alvarez R., Fitzgerald K., Gamba-Vitalo C., Nochur S.V., Vaishnaw A.K., Sah D.W., Gollob J.A., Suhr O.B. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 2013, 369(9):819-829.
4. Graham M.J., Lee R.G., Bell T.A., Fu W., Mullick A.E., Alexander V.J., Singleton W., Viney N., Geary R., Su J., Baker B.F., Burkey J., Crooke S.T., Crooke R.M. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ. Res. 2013, 112(11):1479-1490.
5. Tanioka M., Nokihara H., Yamamoto N., Yamada Y., Yamada K., Goto Y., Fujimoto T., Sekiguchi R., Uenaka K., Callies S., Tamura T. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2011, 68(2):505-511.
6. Mack G.S. MicroRNA gets down to business. Nat. Biotechnol. 2007, 25(6):631-638.
7. Kang S., Im K., Baek J., Yoon S., Min H. Macro and small over micro: macromolecules and small molecules that regulate microRNAs. Chembiochem 2014, 15(8):1071-1078.
8. Taibi F., Metzinger-Le Meuth V., Massy Z.A., Metzinger L. miR-223: an inflammatory oncomiR enters the cardiovascular field. Biochim. Biophys. Acta 2014, 1842(7):1001-1009.
9. Greene C.M., Gaughan K.P. microRNAs in asthma: potential therapeutic targets. Curr. Opin. Pulm. Med. 2013, 19(1):66-72.
10. Bonauer A., Carmona G., Iwasaki M., Mione M., Koyanagi M., Fischer A., Burchfield J., Fox H., Doebele C., Ohtani K., Chavakis E., Potente M., Tjwa M., Urbich C., Zeiher A.M., Dimmeler S. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009, 324(5935):1710-1713.
11. Weiland M., Gao X.H., Zhou L., Mi Q.S. Small RNAs have a large impact circulating microRNAs as biomarkers for human diseases. RNA Biol. 2012, 9(6):850-859.
12. Hullinger T.G., Montgomery R.L., Seto A.G., Dickinson B.A., Semus H.M., Lynch J.M., Dalby C.M., Robinson K., Stack C., Latimer P.A., Hare J.M., Olson E.N., van Rooij E. Inhibition of miR-15 protects against cardiac ischemic injury. Circ. Res. 2012, 110(1):71-81.
13. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., Kauppinen S., Orum H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327(5962):198-201.
14. Rayner K.J., Esau C.C., Hussain F.N., McDaniel A.L., Marshall S.M., van Gils J.M., Ray T.D., Sheedy F.J., Goedeke L., Liu X., Khatsenko O.G., Kaimal V., Lees C.J., Fernandez-Hernando C., Fisher E.A., Temel R.E., Moore K.J. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011, 478(7369):404-407.
15. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., van der Meer A.J., Patick A.K., Chen A., Zhou Y., Persson R., King B.D., Kauppinen S., Levin A.A., Hodges M.R. Treatment of HCV infection by targeting microRNA. N. Engl. J. Med. 2013, 368(18):1685-1694.
16. Garzon R., Marcucci G., Croce C.M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 2010, 9(10):775-789.
17. Gregory R.I., Chendrimada T.P., Cooch N., Shiekhattar R. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell 2005, 123(4):631-640.
18. Lee Y.S., Kim H.K., Chung S., Kim K.S., Dutta A. Depletion of human micro-RNA miR-125b reveals that it is critical for the proliferation of differentiated cells but not for the down-regulation of putative targets during differentiation. J. Biol. Chem. 2005, 280(17):16635-16641.
19. Lennox K.A., Behlke M.A. Chemical modification and design of anti-miRNA oligonucleotides. Gene Ther. 2011, 18(12):1111-1120.
20. Li Z., Rana T.M. Therapeutic targeting of microRNAs: current status and future challenges. Nat. Rev. Drug Discov. 2014, 13(8):622-638.
21. Kloosterman W.P., Lagendijk A.K., Ketting R.F., Moulton J.D., Plasterk R.H. Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biol. 2007, 5(8):e203.
22. Young J.A., Ting K.K., Li J., Moller T., Dunn L., Lu Y., Moses J., Prado-Lourenco L., Khachigian L.M., Ng M., Gregory P.A., Goodall G.J., Tsykin A., Lichtenstein I., Hahn C.N., Tran N., Shackel N., Kench J.G., McCaughan G., Vadas M.A., Gamble J.R. Regulation of vascular leak and recovery from ischemic injury by general and VE-cadherin-restricted miRNA antagonists of miR-27. Blood 2013, 122(16):2911-2919.
23. Lennox K.A., Owczarzy R., Thomas D.M., Walder J.A., Behlke M.A. Improved performance of anti-miRNA oligonucleotides using a novel non-nucleotide modifier. Mol. Ther. Nucleic Acids 2013, 2:e117.
24. Boutla A., Delidakis C., Tabler M. Developmental defects by antisense-mediated inactivation of micro-RNAs 2 and 13 in Drosophila and the identification of putative target genes. Nucleic Acids Res. 2003, 31(17):4973-4980.
25. Hutvagner G., Simard M.J., Mello C.C., Zamore P.D. Sequence-specific inhibition of small RNA function. PLoS Biol. 2004, 2(4):E98.
26. Lennox K.A., Sabel J.L., Johnson M.J., Moreira B.G., Fletcher C.A., Rose S.D., Behlke M.A., Laikhter A.L., Walder J.A., Dagle J.M. Characterization of modified antisense oligonucleotides in Xenopus laevis embryos. Oligonucleotides 2006, 16(1):26-42.
27. Krutzfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438(7068):685-689.
28. Krutzfeldt J., Kuwajima S., Braich R., Rajeev K.G., Pena J., Tuschl T., Manoharan M., Stoffel M. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 2007, 35(9):2885-2892.
29. Liu N., Bezprozvannaya S., Williams A.H., Qi X., Richardson J.A., Bassel-Duby R., Olson E.N. MicroRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev. 2008, 22(23):3242-3254.
30. Morrisey E.E. The magic and mystery of miR-21. J. Clin. Invest. 2010, 120(11):3817-3819.
31. Patrick D.M., Montgomery R.L., Qi X., Obad S., Kauppinen S., Hill J.A., van Rooij E., Olson E.N. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J. Clin. Invest. 2010, 120(11):3912-3916.
32. Obad S., dos Santos C.O., Petri A., Heidenblad M., Broom O., Ruse C., Fu C., Lindow M., Stenvang J., Straarup E.M., Hansen H.F., Koch T., Pappin D., Hannon G.J., Kauppinen S. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 2011, 43(4):371-378.
33. Fabani M.M., Gait M.J. MiR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA 2008, 14(2):336-346.
34. Janson C.G., During M.J. Peptide nucleic acids, morpholinos and related antisense biomolecules 2007, Springer US.
35. Natsume T., Ishikawa Y., Dedachi K., Tsukamoto T., Kurita N. Hybridization energies of double strands composed of DNA, RNA, PNA and LNA. Chem. Phys. Lett. 2007, 434(1-3):133-138.
36. Nielsen P.E. Applications of peptide nucleic acids. Curr. Opin. Biotechnol. 1999, 10(1):71-75.
37. Oh S.Y., Ju Y., Park H. A highly effective and long-lasting inhibition of miRNAs with PNA-based antisense oligonucleotides. Mol. Cells 2009, 28(4):341-345.
38. Ratilainen T., Holmen A., Tuite E., Nielsen P.E., Norden B. Thermodynamics of sequence-specific binding of PNA to DNA. Biochemistry-Us 2000, 39(26):7781-7791.
39. Braasch D.A., Corey D.R. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem. Biol. 2001, 8(1):1-7.
40. Aartsma-Rus A., Kaman W.E., Bremmer-Bout M., Janson A.A., den Dunnen J.T., van Ommen G.J., van Deutekom J.C. Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. Gene Ther. 2004, 11(18):1391-1398.
41. Ida H., Tachibana A., Tanabe T. Binding affinity of ssDNA is improved by attachment of dsDNA regions. J. Biosci. Bioeng. 2014, 118(3):239-241.
42. Tachibana A., Yamada Y., Ida H., Saito S., Tanabe T. LidNA, a novel miRNA inhibitor constructed with unmodified DNA. FEBS Lett. 2012, 586(10):1529-1532.
43. Tay F.C., Lim J.K., Zhu H., Hin L.C., Wang S. Using artificial microRNA sponges to achieve microRNA loss-of-function in cancer cells. Adv. Drug Deliv. Rev. 2014, 81:117-127.
44. Salmena L., Poliseno L., Tay Y., Kats L., Pandolfi P.P. A ceRNA hypothesis: the Rosetta stone of a hidden RNA language?. Cell 2011, 146(3):353-358.
45. Poliseno L., Salmena L., Zhang J., Carver B., Haveman W.J., Pandolfi P.P. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature 2010, 465(7301):1033-1038.
46. Hansen T.B., Jensen T.I., Clausen B.H., Bramsen J.B., Finsen B., Damgaard C.K., Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature 2013, 495(7441):384-388.
47. Ebert M.S., Sharp P.A. MicroRNA sponges: progress and possibilities. RNA 2010, 16(11):2043-2050.
48. Ebert M.S., Neilson J.R., Sharp P.A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 2007, 4(9):721-726.
49. Liu Y., Han Y., Zhang H., Nie L., Jiang Z., Fa P., Gui Y., Cai Z. Synthetic miRNA-mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS One 2012, 7(12):e52280.
50. Haraguchi T., Ozaki Y., Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 2009, 37(6):e43.
51. Starczynowski D.T., Kuchenbauer F., Argiropoulos B., Sung S., Morin R., Muranyi A., Hirst M., Hogge D., Marra M., Wells R.A., Buckstein R., Lam W., Humphries R.K., Karsan A. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat. Med. 2010, 16(1):49-58.
52. Papapetrou E.P., Korkola J.E., Sadelain M. A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells. Stem Cells 2010, 28(2):287-296.
53. Gentner B., Schira G., Giustacchini A., Amendola M., Brown B.D., Ponzoni M., Naldini L. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat. Methods 2009, 6(1):63-66.
54. Caporali A., Emanueli C. MicroRNA regulation in angiogenesis. Vascul. Pharmacol. 2011, 55(4):79-86.
55. Rhim C., Cheng C.S., Kraus W.E., Truskey G.A. Effect of microRNA modulation on bioartificial muscle function. Tissue Eng. Part A 2010, 16(12):3589-3597.
56. Sakurai H., Kawabata K., Sakurai F., Nakagawa S., Mizuguchi H. Innate immune response induced by gene delivery vectors. Int. J. Pharm. 2008, 354(1-2):9-15.
57. Deiters A. Small molecule modifiers of the microRNA and RNA interference pathway. AAPS J. 2010, 12(1):51-60.
58. Chiu Y.L., Dinesh C.U., Chu C.Y., Ali A., Brown K.M., Cao H., Rana T.M. Dissecting RNA-interference pathway with small molecules. Chem. Biol. 2005, 12(6):643-648.
59. Gumireddy K., Young D.D., Xiong X., Hogenesch J.B., Huang Q., Deiters A. Small-molecule inhibitors of microRNA miR-21 function. Angew. Chem. Int. Ed. Engl. 2008, 47(39):7482-7484.
60. Connelly C., Deiters A. Identification of inhibitors of microRNA function from small molecule screens. MiRNA Maturation 2014, vol. 1095:147-156. Humana Press. C. Arenz (Ed.).
61. Gooch B.D., Beal P.A. Recognition of duplex RNA by helix-threading peptides. J. Am. Chem. Soc. 2004, 126(34):10603-10610.
62. Zhang S., Chen L., Jung E.J., Calin G.A. Targeting microRNAs with small molecules: between dream and reality. Clin. Pharmacol. Ther. 2010, 87(6):754.
63. Connelly C.M., Thomas M., Deiters A. High-throughput luciferase reporter assay for small-molecule inhibitors of microRNA function. J. Biomol. Screen. 2012, 17(6):822-828.
64. Lu B., Atala A. Small molecules and small molecule drugs in regenerative medicine. Drug Discov. Today 2014, 19(6):801-808.
65. Young D.D., Connelly C.M., Grohmann C., Deiters A. Small molecule modifiers of microRNA miR-122 function for the treatment of hepatitis C virus infection and hepatocellular carcinoma. J. Am. Chem. Soc. 2010, 132(23):7976-7981.
66. Grainger D.W. Cell-based drug testing; this world is not flat. Adv. Drug Deliv. Rev. 2014, 69-70. vii-xi.
67. Nelson C.E., Gupta M.K., Adolph E.J., Shannon J.M., Guelcher S.A., Duvall C.L. Sustained local delivery of siRNA from an injectable scaffold. Biomaterials 2012, 33(4):1154-1161.
68. Prosser H.M., Koike-Yusa H., Cooper J.D., Law F.C., Bradley A. A resource of vectors and ES cells for targeted deletion of microRNAs in mice. Nat. Biotechnol. 2011, 29(9):840-845.
69. Zhu Q.B., Sun W.Y., Okano K., Chen Y., Zhang N., Maeda T., Palczewski K. Sponge transgenic mouse model reveals important roles for the microRNA-183 (miR-183)/96/182 cluster in postmitotic photoreceptors of the retina. J. Biol. Chem. 2011, 286(36):31749-31760.
70. Sun K., Lai E.C. Adult-specific functions of animal microRNAs. Nat. Rev. Genet. 2013, 14(8):535-548.
71. Park C.Y., Jeker L.T., Carver-Moore K., Oh A., Liu H.J., Cameron R., Richards H., Li Z., Adler D., Yoshinaga Y., Martinez M., Nefadov M., Abbas A.K., Weiss A., Lanier L.L., de Jong P.J., Bluestone J.A., Srivastava D., McManus M.T. A resource for the conditional ablation of microRNAs in the mouse. Cell. Reprogram 2012, 1(4):385-391.
72. Baigude H., McCarroll J., Yang C.S., Swain P.M., Rana T.M. Design and creation of new nanomaterials for therapeutic RNAi. ACS Chem. Biol. 2007, 2(4):237-241.
73. Qian X., Long L., Shi Z., Liu C., Qiu M., Sheng J., Pu P., Yuan X., Ren Y., Kang C. Star-branched amphiphilic PLA-b-PDMAEMA copolymers for co-delivery of miR-21 inhibitor and doxorubicin to treat glioma. Biomaterials 2014, 35(7):2322-2335.
74. Kim J.H., Yeom J.H., Ko J.J., Han M.S., Lee K., Na S.Y., Bae J. Effective delivery of anti-miRNA DNA oligonucleotides by functionalized gold nanoparticles. J. Biotechnol. 2011, 155(3):287-292.
75. Kim J.H., Jang H.H., Ryou S.M., Kim S., Bae J., Lee K., Han M.S. A functionalized gold nanoparticles-assisted universal carrier for antisense DNA. Chem. Commun. (Camb.) 2010, 46(23):4151-4153.
76. Beavers K.R., Mares J.W., Swartz C.M., Zhao Y., Weiss S.M., Duvall C.L. In situ synthesis of peptide nucleic acids in porous silicon for drug delivery and biosensing. Bioconjug. Chem. 2014, 25(7):1192-1197.
77. Zhang M., Zhou X., Wang B., Yung B.C., Lee L.J., Ghoshal K., Lee R.J. Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma. J. Control. Release 2013, 168(3):251-261.
78. Shi S.J., Zhong Z.R., Liu J., Zhang Z.R., Sun X., Gong T. Solid lipid nanoparticles loaded with anti-microRNA oligonucleotides (AMOs) for suppression of microRNA-21 functions in human lung cancer cells. Pharm. Res. 2012, 29(1):97-109.
79. Oh S.Y., Ju Y., Kim S., Park H. PNA-based antisense oligonucleotides for microRNAs inhibition in the absence of a transfection reagent. Oligonucleotides 2010, 20(5):225-230.
80. Cheng C.J., Saltzman W.M. Polymer nanoparticle-mediated delivery of microRNA inhibition and alternative splicing. Mol. Pharm. 2012, 9(5):1481-1488.
81. Elmen J., Lindow M., Silahtaroglu A., Bak M., Christensen M., Lind-Thomsen A., Hedtjarn M., Hansen J.B., Hansen H.F., Straarup E.M., McCullagh K., Kearney P., Kauppinen S. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res. 2008, 36(4):1153-1162.
82. Liu X.Q., Song W.J., Sun T.M., Zhang P.Z., Wang J. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol. Pharm. 2011, 8(1):250-259.
83. Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siRNA therapeutics. Nat. Mater. 2013, 12(11):967-977.
84. Carbone E.J., Jiang T., Nelson C., Henry N., Lo K.W. Small molecule delivery through nanofibrous scaffolds for musculoskeletal regenerative engineering. Nanomedicine 2014, 10(8):1691-1699.
85. Kouhi M., Morshed M., Varshosaz J., Fathi M.H. Poly (ε-caprolactone) incorporated bioactive glass nanoparticles and simvastatin nanocomposite nanofibers: preparation, characterization and in vitro drug release for bone regeneration applications. Chem. Eng. J. 2013, 228:1057-1065.
86. Piskin E., Isoglu I.A., Bolgen N., Vargel I., Griffiths S., Cavusoglu T., Korkusuz P., Guzel E., Cartmell S. In vivo performance of simvastatin-loaded electrospun spiral-wound polycaprolactone scaffolds in reconstruction of cranial bone defects in the rat model. J. Biomed. Mater. Res. A 2009, 90(4):1137-1151.
87. Carmody S.R., Wente S.R. mRNA nuclear export at a glance. J. Cell Sci. 2009, 122(12):1933-1937.
88. Wang Z., Zhu T., Qiao C., Zhou L., Wang B., Zhang J., Chen C., Li J., Xiao X. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 2005, 23(3):321-328.
89. Chao H.J., Liu Y.B., Rabinowitz J., Li C.W., Samulski R.J., Walsh C.E. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther. 2000, 2(6):619-623.
90. Mingozzi F., High K.A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 2011, 12(5):341-355.
91. Lin E., Nemunaitis J. Oncolytic viral therapies. Cancer Gene Ther. 2004, 11(10):643-664.
92. Naldini L., Blömer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272(5259):263-267.
93. Gentner B., Schira G., Giustacchini A., Amendola M., Brown B.D., Ponzoni M., Naldini L. Stable knockdown of microRNA in vivo by lentiviral vectors. Nat. Methods 2008, 6(1):63-66.
94. Meloni M., Marchetti M., Garner K., Littlejohns B., Sala-Newby G., Xenophontos N., Floris I., Suleiman M.-S., Madeddu P., Caporali A. Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol. Ther. 2013, 21(7):1390-1402.
95. Xie J., Ameres S.L., Friedline R., Hung J.-H., Zhang Y., Xie Q., Zhong L., Su Q., He R., Li M. Long-term, efficient inhibition of microRNA function in mice using rAAV vectors. Nat. Methods 2012, 9(4):403-409.
96. Haraguchi T., Ozaki Y., Iba H. Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells. Nucleic Acids Res. 2009, 37(6):e43.
97. Kay M.A. State-of-the-art gene-based therapies: the road ahead. Nat. Rev. Genet. 2011, 12(5):316-328.
98. Scherr M., Venturini L., Battmer K., Schaller-Schoenitz M., Schaefer D., Dallmann I., Ganser A., Eder M. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res. 2007, 35(22):e149.
99. Jang J.H., Schaffer D.V., Shea L.D. Engineering biomaterial systems to enhance viral vector gene delivery. Mol. Ther. 2011, 19(8):1407-1415.
100. Logg C.R., Logg A., Matusik R.J., Bochner B.H., Kasahara N. Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J. Virol. 2002, 76(24):12783-12791.
101. Mingozzi F., High K.A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013, 122(1):23-36.
102. Maheshri N., Koerber J.T., Kaspar B.K., Schaffer D.V. Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 2006, 24(2):198-204.
103. Koerber J.T., Jang J.H., Schaffer D.V. DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol. Ther. 2008, 16(10):1703-1709.
104. Knight S., Collins M., Takeuchi Y. Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis. Curr. Gene Ther. 2013, 13(3):211-227.
105. Salvay D.M., Zelivyanskaya M., Shea L.D. Gene delivery by surface immobilization of plasmid to tissue-engineering scaffolds. Gene Ther. 2010, 17(9):1134-1141.
106. Adolph E.J., Nelson C.E., Werfel T.A., Guo R., Davidson J.M., Guelcher S.A., Duvall C.L. Enhanced performance of plasmid DNA polyplexes stabilized by a combination of core hydrophobicity and surface PEGylation. J. Mater. Chem. B 2014, 2(46):8154-8164.
107. Nelson C.E., Kim A.J., Adolph E.J., Gupta M.K., Yu F., Hocking K.M., Davidson J.M., Guelcher S.A., Duvall C.L. Tunable delivery of siRNA from a biodegradable scaffold to promote angiogenesis in vivo. Adv. Mater. 2014, 26(4):607-614. (506).
108. Castleberry S., Wang M., Hammond P.T. Nanolayered siRNA dressing for sustained localized knockdown. ACS Nano 2013, 7(6):5251-5261.
109. Luo D., Saltzman W.M. Synthetic DNA delivery systems. Nat. Biotechnol. 2000, 18(1):33-37.
110. Segura T., Shea L.D. Surface-tethered DNA complexes for enhanced gene delivery. Bioconjug. Chem. 2002, 13(3):621-629.
111. Shea L.D., Smiley E., Bonadio J., Mooney D.J. DNA delivery from polymer matrices for tissue engineering. Nat. Biotechnol. 1999, 17(6):551-554.
112. Thomson D.W., Bracken C.P., Szubert J.M., Goodall G.J. On measuring miRNAs after transient transfection of mimics or antisense inhibitors. PLoS One 2013, 8(1):e55214.
113. Cui L., Liu B., Liu G., Zhang W., Cen L., Sun J., Yin S., Liu W., Cao Y. Repair of cranial bone defects with adipose derived stem cells and coral scaffold in a canine model. Biomaterials 2007, 28(36):5477-5486.
114. Moioli E.K., Clark P.A., Xin X., Lal S., Mao J.J. Matrices and scaffolds for drug delivery in dental, oral and craniofacial tissue engineering. Adv. Drug Deliv. Rev. 2007, 59(4-5):308-324.
115. Bose S., Roy M., Bandyopadhyay A. Recent advances in bone tissue engineering scaffolds. Trends Biotechnol. 2012, 30(10):546-554.
116. Dumas J.E., Prieto E.M., Zienkiewicz K.J., Guda T., Wenke J.C., Bible J., Holt G.E., Guelcher S.A. Balancing the rates of new bone formation and polymer degradation enhances healing of weight-bearing allograft/polyurethane composites in rabbit femoral defects. Tissue Eng. Part A 2014, 20(1-2):115-129.
117. Priddy L.B., Chaudhuri O., Stevens H.Y., Krishnan L., Uhrig B.A., Willett N.J., Guldberg R.E. Oxidized alginate hydrogels for bone morphogenetic protein-2 delivery in long bone defects. Acta Biomater. 2014, 10(10):4390-4399.
118. Nguyen M.K., Jeon O., Krebs M.D., Schapira D., Alsberg E. Sustained localized presentation of RNA interfering molecules from in situ forming hydrogels to guide stem cell osteogenic differentiation. Biomaterials 2014, 35(24):6278-6286.
119. Zou D., Zhang Z., He J., Zhang K., Ye D., Han W., Zhou J., Wang Y., Li Q., Liu X., Zhang X., Wang S., Hu J., Zhu C., Zhang W., Zhou Y., Fu H., Huang Y., Jiang X. Blood vessel formation in the tissue-engineered bone with the constitutively active form of HIF-1alpha mediated BMSCs. Biomaterials 2012, 33(7):2097-2108.
120. 165 and BMP-2 delivery for elevation of the maxillary sinus floor. Biomaterials 2011, 32(35):9415-9424.
121. Xiao W., Fu H., Rahaman M.N., Liu Y., Bal B.S. Hollow hydroxyapatite microspheres: a novel bioactive and osteoconductive carrier for controlled release of bone morphogenetic protein-2 in bone regeneration. Acta Biomater. 2013, 9(9):8374-8383.
122. Kim M.J., Lee B., Yang K., Park J., Jeon S., Um S.H., Kim D.I., Im S.G., Cho S.W. BMP-2 peptide-functionalized nanopatterned substrates for enhanced osteogenic differentiation of human mesenchymal stem cells. Biomaterials 2013, 34(30):7236-7246.
123. Ding H., Gao Y.-S., Hu C., Wang Y., Wang C.-G., Yin J.-M., Sun Y., Zhang C.-Q. HIF-1α transgenic bone marrow cells can promote tissue repair in cases of corticosteroid-induced osteonecrosis of the femoral head in rabbits. PLoS One 2013, 8(5):e63628.
124. Shen X., Wan C., Ramaswamy G., Mavalli M., Wang Y., Duvall C.L., Deng L.F., Guldberg R.E., Eberhart A., Clemens T.L., Gilbert S.R. Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. J. Orthop. Res. 2009, 27(10):1298-1305.
125. Yau W.W., Rujitanaroj P.O., Lam L., Chew S.Y. Directing stem cell fate by controlled RNA interference. Biomaterials 2012, 33(9):2608-2628.
126. Li Y., Fan L., Liu S., Liu W., Zhang H., Zhou T., Wu D., Yang P., Shen L., Chen J. The promotion of bone regeneration through positive regulation of angiogenic-osteogenic coupling using microRNA-26a. Biomaterials 2013, 34(21):5048-5058.
127. Murata K., Ito H., Yoshitomi H., Yamamoto K., Fukuda A., Yoshikawa J., Furu M., Ishikawa M., Shibuya H., Matsuda S. Inhibition of miR-92a enhances fracture healing via promoting angiogenesis in a model of stabilized fracture in young mice. J. Bone Miner. Res. 2014, 29(2):316-326.
128. Kosaka N., Iguchi H., Yoshioka Y., Hagiwara K., Takeshita F., Ochiya T. Competitive interactions of cancer cells and normal cells via secretory microRNAs. J. Biol. Chem. 2012, 287(2):1397-1405.
129. Suh J.S., Lee J.Y., Choi Y.S., Chung C.P., Park Y.J. Peptide-mediated intracellular delivery of miRNA-29b for osteogenic stem cell differentiation. Biomaterials 2013, 34(17):4347-4359.
130. Deng Y., Wu S., Zhou H., Bi X., Wang Y., Hu Y., Gu P., Fan X. Effects of a miR-31, Runx2, and Satb2 regulatory loop on the osteogenic differentiation of bone mesenchymal stem cells. Stem Cells Dev. 2013, 22(16):2278-2286.
131. Deng Y., Bi X., Zhou H., You Z., Wang Y., Gu P., Fan X. Repair of critical-sized bone defects with anti-miR-31-expressing bone marrow stromal stem cells and poly(glycerol sebacate) scaffolds. Eur. Cell Mater. 2014, 27:13-24. (discussion 24-5).
132. Fausto N. Liver regeneration. J. Hepatol. 2000, 32(1 Suppl.):19-31.
133. Bucher N.L., Farmer S.R. Liver regeneration following partial hepatectomy: genes and metabolism. Liver Growth and Repair 1998, 3-27. Springer.
134. Current U.S. organ transplant waiting list (accessed September 6). http://optn.transplant.hrsa.gov/latestData/rptData.asp.
135. Song G., Sharma A.D., Roll G.R., Ng R., Lee A.Y., Blelloch R.H., Frandsen N.M., Willenbring H. MicroRNAs control hepatocyte proliferation during liver regeneration. Hepatology 2010, 51(5):1735-1743.
136. Pan C., Chen H., Wang L., Yang S., Fu H., Zheng Y., Miao M., Jiao B. Down-regulation of MiR-127 facilitates hepatocyte proliferation during rat liver regeneration. PLoS One 2012, 7(6):e39151.
137. Ranuncolo S.M., Polo J.M., Dierov J., Singer M., Kuo T., Greally J., Green R., Carroll M., Melnick A. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat. Immunol. 2007, 8(7):705-714.
138. Jørgensen S., Elvers I., Trelle M.B., Menzel T., Eskildsen M., Jensen O.N., Helleday T., Helin K., Sørensen C.S. The histone methyltransferase SET8 is required for S-phase progression. J. Cell Biol. 2007, 179(7):1337-1345.
139. Chen H., Sun Y.M., Dong R.Q., Yang S.S., Pan C.Y., Xiang D., Miao M.Y., Jiao B.H. Mir-34a is upregulated during liver regeneration in rats and is associated with the suppression of hepatocyte proliferation. PLoS One 2011, 6(5):e20238.
140. Little M.H. Regrow or repair: potential regenerative therapies for the kidney. J. Am. Soc. Nephrol. 2006, 17(9):2390-2401.
141. Strutz F., Okada H., Lo C.W., Danoff T., Carone R.L., Tomaszewski J.E., Neilson E.G. Identification and characterization of a fibroblast marker: FSP1. J. Cell Biol. 1995, 130(2):393-405.
142. Witzgall R., Brown D., Schwarz C., Bonventre J.V. Localization of proliferating cell nuclear antigen, vimentin, c-Fos, and clusterin in the postischemic kidney - evidence for a heterogenous genetic response among nephron segments, and a large pool of mitotically active and dedifferentiated cells. J. Clin. Investig. 1994, 93(5):2175-2188.
143. Bonventre J.V. Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J. Am. Soc. Nephrol. 2003, 14(Suppl. 1):S55-S61.
144. Imasawa T., Utsunomiya Y., Kawamura T., Zhong Y., Nagasawa R., Okabe M., Maruyama N., Hosoya T., Ohno T. The potential of bone marrow-derived cells to differentiate to glomerular mesangial cells. J. Am. Soc. Nephrol. 2001, 12(7):1401-1409.
145. Poulsom R., Forbes S.J., Hodivala-Dilke K., Ryan E., Wyles S., Navaratnarasah S., Jeffery R., Hunt T., Alison M., Cook T., Pusey C., Wright N.A. Bone marrow contributes to renal parenchymal turnover and regeneration. J. Pathol. 2001, 195(2):229-235.
146. Cantaluppi V., Gatti S., Medica D., Figliolini F., Bruno S., Deregibus M.C., Sordi A., Biancone L., Tetta C., Camussi G. Microvesicles derived from endothelial progenitor cells protect the kidney from ischemia-reperfusion injury by microRNA-dependent reprogramming of resident renal cells. Kidney Int. 2012, 82(4):412-427.
147. Kato M., Zhang J., Wang M., Lanting L., Yuan H., Rossi J.J., Natarajan R. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. PNAS 2007, 104(9):3432-3437.
148. Kato M., Arce L., Natarajan R. MicroRNAs and their role in progressive kidney diseases. Clin. J. Am. Soc. Nephrol. 2009, 4(7):1255-1266.
149. Elmen J., Lindow M., Schutz S., Lawrence M., Petri A., Obad S., Lindholm M., Hedtjarn M., Hansen H.F., Berger U., Gullans S., Kearney P., Sarnow P., Straarup E.M., Kauppinen S. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452(7189):896-899.
150. Long J.Y., Wang Y., Wang W.J., Chang B.H.J., Danesh F.R. Identification of microRNA-93 as a novel regulator of vascular endothelial growth factor in hyperglycemic conditions. J. Biol. Chem. 2010, 285(30):23455-23463.
151. Zarjou A., Yang S., Abraham E., Agarwal A., Liu G. Identification of a microRNA signature in renal fibrosis: role of miR-21. Am. J. Physiol. Renal Physiol. 2011, 301(4):F793-F801.
152. Putta S., Lanting L., Sun G., Lawson G., Kato M., Natarajan R. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J. Am. Soc. Nephrol. 2012, 23(3):458-469.
153. Luo W., Nie Q., Zhang X. MicroRNAs involved in skeletal muscle differentiation. J. Genet Genomics 2013, 40(3):107-116.
154. Chen J.F., Tao Y., Li J., Deng Z., Yan Z., Xiao X., Wang D.Z. MicroRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7. J. Cell Biol. 2010, 190(5):867-879.
155. Lepper C., Partridge T.A., Fan C.M. An absolute requirement for Pax7-positive satellite cells in acute injury-induced skeletal muscle regeneration. Development 2011, 138(17):3639-3646.
156. Sambasivan R., Yao R., Kissenpfennig A., Van Wittenberghe L., Paldi A., Gayraud-Morel B., Guenou H., Malissen B., Tajbakhsh S., Galy A. Pax7-expressing satellite cells are indispensable for adult skeletal muscle regeneration. Development 2011, 138(17):3647-3656.
157. Murphy M.M., Lawson J.A., Mathew S.J., Hutcheson D.A., Kardon G. Satellite cells, connective tissue fibroblasts and their interactions are crucial for muscle regeneration. Development 2011, 138(17):3625-3637.
158. Liu N., Williams A.H., Maxeiner J.M., Bezprozvannaya S., Shelton J.M., Richardson J.A., Bassel-Duby R., Olson E.N. MicroRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. J. Clin. Invest. 2012, 122(6):2054-2065.
159. Williams A.H., Valdez G., Moresi V., Qi X., McAnally J., Elliott J.L., Bassel-Duby R., Sanes J.R., Olson E.N. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009, 326(5959):1549-1554.
160. Yan B., Guo J.T., Zhu C.D., Zhao L.H., Zhao J.L. MiR-203b: a novel regulator of MyoD expression in tilapia skeletal muscle. J. Exp. Biol. 2013, 216(Pt 3):447-451.
161. Bonow R.O., Mann D.L., Zipes D.P., Libby P. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine 2011, Elsevier Health Sciences.
162. Wahlquist C., Jeong D., Rojas-Munoz A., Kho C., Lee A., Mitsuyama S., van Mil A., Park W.J., Sluijter J.P., Doevendans P.A., Hajjar R.J., Mercola M. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 2014, 508(7497):531-535.
163. Wahlquist C., Jeong D., Rojas-Muñoz A., Kho C., Lee A., Mitsuyama S., van Mil A., Park W.J., Sluijter J.P., Doevendans P.A. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 2014, 508(7497):531-535.
164. Meloni M., Marchetti M., Garner K., Littlejohns B., Sala-Newby G., Xenophontos N., Floris I., Suleiman M.S., Madeddu P., Caporali A., Emanueli C. Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction. Mol. Ther. 2013, 21(7):1390-1402.
165. Fujita M., Otani H., Iwasaki M., Yoshioka K., Shimazu T., Shiojima I., Tabata Y. Antagomir-92a impregnated gelatin hydrogel microsphere sheet enhances cardiac regeneration after myocardial infarction in rats. Exp. Clin. Cardiol. 2014, 20(1):1762-1787.
166. Small E.M., Frost R.J., Olson E.N. MicroRNAs add a new dimension to cardiovascular disease. Circulation 2010, 121(8):1022-1032.
167. Wang C., Wang S., Zhao P., Wang X., Wang J., Wang Y., Song L., Zou Y., Hui R. MiR-221 promotes cardiac hypertrophy in vitro through the modulation of p27 expression. J. Cell. Biochem. 2012, 113(6):2040-2046.
168. van Rooij E., Sutherland L.B., Qi X., Richardson J.A., Hill J., Olson E.N. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007, 316(5824):575-579.
169. van Rooij E., Marshall W.S., Olson E.N. Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ. Res. 2008, 103(9):919-928.
170. Caporali A., Meloni M., Vollenkle C., Bonci D., Sala-Newby G.B., Addis R., Spinetti G., Losa S., Masson R., Baker A.H., Agami R., le Sage C., Condorelli G., Madeddu P., Martelli F., Emanueli C. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011, 123(3):282-291.
171. Doebele C., Bonauer A., Fischer A., Scholz A., Reiss Y., Urbich C., Hofmann W.K., Zeiher A.M., Dimmeler S. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 2010, 115(23):4944-4950.
172. Roy S., Sen C.K. MiRNA in wound inflammation and angiogenesis. Microcirculation 2012, 19(3):224-232.
173. Banerjee J., Chan Y.C., Sen C.K. MicroRNAs in skin and wound healing. Physiol. Genomics 2011, 43(10):543-556.
174. Mills S.J., Cowin A.J. MicrorNAs and their roles in wound repair and regeneration. Wound Pract. Res. J. Aust. Wound Manage. Assoc. 2013, 21(1):26.
175. Funari V.A., Winkler M., Brown J., Dimitrijevich S.D., Ljubimov A.V., Saghizadeh M. Differentially expressed wound healing-related microRNAs in the human diabetic cornea. PLoS One 2013, 8(12):e84425.
176. Hezova R., Slaby O., Faltejskova P., Mikulkova Z., Buresova I., Raja K.R., Hodek J., Ovesna J., Michalek J. MicroRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell. Immunol. 2010, 260(2):70-74.
177. Sand M., Gambichler T., Sand D., Skrygan M., Altmeyer P., Bechara F.G. MicroRNAs and the skin: tiny players in the body's largest organ. J. Dermatol. Sci. 2009, 53(3):169-175.
178. Pastar I., Khan A.A., Stojadinovic O., Lebrun E.A., Medina M.C., Brem H., Kirsner R.S., Jimenez J.J., Leslie C., Tomic-Canic M. Induction of specific microRNAs inhibits cutaneous wound healing. J. Biol. Chem. 2012, 287(35):29324-29335.
179. Wetzler C., Kampfer H., Stallmeyer B., Pfeilschifter J., Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J. Invest. Dermatol. 2000, 115(2):245-253.
180. Graves D., Dasu M.R. Advances in Wound Care: Volume 2. Inflammation Impairs Wound Healing in Diabetic Mice 2011.
181. Tili E., Michaille J.J., Cimino A., Costinean S., Dumitru C.D., Adair B., Fabbri M., Alder H., Liu C.G., Calin G.A., Croce C.M. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 2007, 179(8):5082-5089.
182. Murphy A.J., Guyre P.M., Pioli P.A. Estradiol suppresses NF-κB activation through coordinated regulation of let-7a and miR-125b in primary human macrophages. J. Immunol. 2010, 184(9):5029-5037.
183. Brown P.N., Yin H. PNA-based microRNA inhibitors elicit anti-inflammatory effects in microglia cells. Chem. Commun. (Camb.) 2013, 49(39):4415-4417.
184. Li H., Chang L., Du W.W., Gupta S., Khorshidi A., Sefton M., Yang B.B. Anti-microRNA-378a enhances wound healing process by upregulating integrin beta-3 and vimentin. Mol. Ther. 2014, 22(10):1839-1850.
185. Feng B., Chen S., Zhang L., Cao Y., Chakrabarti S. MiRNA-146a and miRNA-200b antagomirs accelerate wound healing through the regulation of VEGF and fibronectin. J. Pharm. Pharmacol. 2014, 2:104-113.
186. Feng B., Chen S., McArthur K., Wu Y., Sen S., Ding Q., Feldman R.D., Chakrabarti S. MiR-146a-mediated extracellular matrix protein production in chronic diabetes complications. Diabetes 2011, 60(11):2975-2984.
187. McArthur K., Feng B., Wu Y., Chen S., Chakrabarti S. MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 2011, 60(4):1314-1323.
188. Biswas S., Roy S., Banerjee J., Hussain S.R., Khanna S., Meenakshisundaram G., Kuppusamy P., Friedman A., Sen C.K. Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. PNAS 2010, 107(15):6976-6981.
189. Sundaram G.M., Common J.E.A., Gopal F.E., Srikanta S., Lakshman K., Lunny D.P., Lim T.C., Tanavde V., Lane E.B., Sampath P. 'See-saw' expression of microRNA-198 and FSTL1 from a single transcript in wound healing. Nature 2013, 495(7439):103-106.
190. Poliseno L., Tuccoli A., Mariani L., Evangelista M., Citti L., Woods K., Mercatanti A., Hammond S., Rainaldi G. MicroRNAs modulate the angiogenic properties of HUVECs 2006, 108:3068-3071.
191. Wang X.H., Qian R.Z., Zhang W., Chen S.F., Jin H.M., Hu R.M. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin. Exp. Pharmacol. Physiol. 2009, 36(2):181-188.
192. Choi Y.C., Yoon S., Jeong Y., Yoon J., Baek K. Regulation of vascular endothelial growth factor signaling by miR-200b. Mol. Cells 2011, 32(1):77-82.
193. Chan Y.C., Khanna S., Roy S., Sen C.K. MiR-200b targets Ets-1 and is down-regulated by hypoxia to induce angiogenic response of endothelial cells. J. Biol. Chem. 2011, 286(3):2047-2056.
194. Caporali A., Meloni M., Völlenkle C., Bonci D., Sala-Newby G.B., Addis R., Spinetti G., Losa S., Masson R., Baker A.H. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011, 123(3):282-291.
195. Larson B.J., Longaker M.T., Lorenz H.P. Scarless fetal wound healing: a basic science review. Plast. Reconstr. Surg. 2010, 126(4):1172-1180.
196. Cheng J., Yu H., Deng S., Shen G. MicroRNA profiling in mid- and late-gestational fetal skin: implication for scarless wound healing. Tohoku J. Exp. Med. 2010, 221(3):203-209.
197. Yin V.P., Thomson J.M., Thummel R., Hyde D.R., Hammond S.M., Poss K.D. Fgf-dependent depletion of microRNA-133 promotes appendage regeneration in zebrafish. Genes Dev. 2008, 22(6):728-733.
198. Bowen T., Jenkins R.H., Fraser D.J. MicroRNAs, transforming growth factor beta-1, and tissue fibrosis. J. Pathol. 2013, 229(2):274-285.
199. Chau B.N., Xin C., Hartner J., Ren S., Castano A.P., Linn G., Li J., Tran P.T., Kaimal V., Huang X., Chang A.N., Li S., Kalra A., Grafals M., Portilla D., MacKenna D.A., Orkin S.H., Duffield J.S. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci. Transl. Med. 2012, 4(121):121ra18.
200. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., Galuppo P., Just S., Rottbauer W., Frantz S., Castoldi M., Soutschek J., Koteliansky V., Rosenwald A., Basson M.A., Licht J.D., Pena J.T., Rouhanifard S.H., Muckenthaler M.U., Tuschl T., Martin G.R., Bauersachs J., Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456(7224):980-984.
201. Liu G., Friggeri A., Yang Y., Milosevic J., Ding Q., Thannickal V.J., Kaminski N., Abraham E. MiR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med. 2010, 207(8):1589-1597.
202. Wang T., Feng Y., Sun H., Zhang L., Hao L., Shi C., Wang J., Li R., Ran X., Su Y., Zou Z. MiR-21 regulates skin wound healing by targeting multiple aspects of the healing process. Am. J. Pathol. 2012, 181(6):1911-1920.
203. van Rooij E., Purcell A.L., Levin A.A. Developing microRNA therapeutics. Circ. Res. 2012, 110(3):496-507.
204. Hydbring P., Badalian-Very G. Clinical applications of microRNAs. F1000Res. 2013, 2:136.
205. Gabriely G., Wurdinger T., Kesari S., Esau C.C., Burchard J., Linsley P.S., Krichevsky A.M. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol. 2008, 28(17):5369-5380.
206. Koval E.D., Shaner C., Zhang P., du Maine X., Fischer K., Tay J., Chau B.N., Wu G.F., Miller T.M. Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. Hum. Mol. Genet. 2013, 22(20):4127-4135.
207. Grueter C.E., van Rooij E., Johnson B.A., DeLeon S.M., Sutherland L.B., Qi X., Gautron L., Elmquist J.K., Bassel-Duby R., Olson E.N. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 2012, 149(3):671-683.
208. Montgomery R.L., Hullinger T.G., Semus H.M., Dickinson B.A., Seto A.G., Lynch J.M., Stack C., Latimer P.A., Olson E.N., van Rooij E. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011, 124(14):1537-1547.
209. Porrello E.R., Mahmoud A.I., Simpson E., Johnson B.A., Grinsfelder D., Canseco D., Mammen P.P., Rothermel B.A., Olson E.N., Sadek H.A. Regulation of neonatal and adult mammalian heart regeneration by the miR-15 family. PNAS 2013, 110(1):187-192.